Cargando…
Improved Endpoints for Cancer Immunotherapy Trials
Unlike chemotherapy, which acts directly on the tumor, cancer immunotherapies exert their effects on the immune system and demonstrate new kinetics that involve building a cellular immune response, followed by changes in tumor burden or patient survival. Thus, adequate design and evaluation of some...
Autores principales: | Hoos, Axel, Eggermont, Alexander M. M., Janetzki, Sylvia, Hodi, F. Stephen, Ibrahim, Ramy, Anderson, Aparna, Humphrey, Rachel, Blumenstein, Brent, Old, Lloyd, Wolchok, Jedd |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943524/ https://www.ncbi.nlm.nih.gov/pubmed/20826737 http://dx.doi.org/10.1093/jnci/djq310 |
Ejemplares similares
-
Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring
por: Hoos, Axel, et al.
Publicado: (2012) -
Combination immunotherapy: a road map
por: Ott, Patrick A., et al.
Publicado: (2017) -
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013) -
Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014) -
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium
por: Britten, Cedrik Michael, et al.
Publicado: (2009)